Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

This study has been completed.
Sponsor:
Collaborators:
Amgen
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00398372
First received: November 9, 2006
Last updated: May 31, 2011
Last verified: July 2010
  Purpose

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.


Condition Intervention
Lymphoma, Non-Hodgkin
Lymphomas: Non-Hodgkin
Lymphomas: Non-Hodgkin Cutaneous Lymphoma
Lymphomas: Non-Hodgkin Diffuse Large B-Cell
Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell
Lymphomas: Non-Hodgkin Mantle Cell
Lymphomas: Non-Hodgkin Marginal Zone
Lymphomas: Non-Hodgkin Peripheral T-Cell
Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia
Drug: Rituximab
Drug: Epratuzumab

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To characterize the molecular and cell biology of the tumor cells in lymphoma. [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 500
Study Start Date: November 2000
Study Completion Date: September 2009
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00398372

Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Amgen
Investigators
Principal Investigator: Wen-Kai Weng Stanford University
  More Information

No publications provided

Responsible Party: Wen-Kai Weng, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00398372     History of Changes
Other Study ID Numbers: LYMNHL0031, 200114861, 77550, CA09287, CA111827, LYMNHL0031
Study First Received: November 9, 2006
Last Updated: May 31, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Waldenstrom Macroglobulinemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Rituximab
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions
Antirheumatic Agents
Therapeutic Uses
Antineoplastic Agents

ClinicalTrials.gov processed this record on April 15, 2014